Image

India's First Indigenous ASF Vaccine Developed by ICAR-NIHSAD

India's First Indigenous ASF Vaccine Developed by ICAR-NIHSAD

Overview :

ICAR announced India's first indigenous African Swine Fever vaccine on August 4, 2026, developed at ICAR-NIHSAD, Bhopal. The live attenuated vaccine targets ASFV Genotype II and is recommended for healthy pigs above eight weeks. ASF caused ₹276 crore losses in Assam and ₹982 crore in Mizoram, highlighting the vaccine's significance.

Understanding African Swine Fever

Think of ASF as a plague for pigs. It causes near-total mortality in infected herds. Unlike COVID-19, ASF doesn't infect humans—but it devastates livelihoods. Pork is a primary protein source in Northeast India, making this disease both a food security and economic issue.

The Vaccine Technology

The vaccine uses a live attenuated approach—weakening the virus so it triggers immunity without causing disease. Think of it as training the immune system with a sparring partner, not a real opponent. The MA-104 cell line provides a stable platform for vaccine production.

Economic Impact

ASF losses in Assam (₹276 crore) and Mizoram (₹982 crore) represent destroyed livelihoods. More than 11,382 households in Mizoram alone suffered income loss. Pigs aren't just livestock—they're household assets and emergency funds. The vaccine protects these assets.

Why ASF Genotype II Matters

Genotype II is the strain responsible for outbreaks in Asia and Europe. Targeting this genotype means the vaccine addresses the specific threat India faces. It's like creating a tailored defence against the most dangerous enemy.

The North-East Focus

Pig farming concentrates in India's north-eastern states where pork is culturally and economically significant. The vaccine's first impact will likely be in these regions—protecting vulnerable communities.

Livestock Biosecurity

The vaccine complements biosecurity measures—movement control, surveillance, and culling. Think of it as adding vaccination to an existing defence system, not replacing it.


Exam-Focused Points :

  • Announcement date  August 4, 2026, by Indian Council of Agricultural Research

  • Developer  ICAR–National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal

  • Dedication ceremony  98th ICAR Foundation Day, July 16, 2026, New Delhi

  • Virus family  Asfarviridae (double-stranded DNA virus)

  • Vaccine type  MA-104 cell line-based live attenuated vaccine

  • Target genotype  ASFV Genotype II (major strain in Asia and Europe)

  • Dosage  1 ml intramuscular injection + booster after 14 days; for healthy pigs above 8 weeks

 


FAQs :

Q1: What is African Swine Fever?
A highly contagious viral disease of domestic pigs and wild suids, caused by ASFV. It does not infect humans.

Q2: Who developed India's ASF vaccine?
ICAR-NIHSAD, Bhopal, under the Indian Council of Agricultural Research.

Q3: What type of vaccine is it?
Live attenuated vaccine using a weakened ASFV Genotype II virus.

Q4: What are the economic losses caused by ASF in India?
₹276 crore in Assam (2020-2021) and ₹982 crore in Mizoram (up to 2025), affecting over 11,382 households.

Q5: When will the vaccine be commercially available?
In about six months, after auction, patenting, and manufacturing by a pharmaceutical company.

Month: 

Category: 

1